Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by Ciaoon Dec 05, 2020 2:38pm
133 Views
Post# 32044366

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Ceapro % Ownership

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Ceapro % Ownershipjust to add Westcoast's reply,

here is how the cash position has looked over the past few quarters with the most recent (ending Sept. 30) on the left, so we are comfortable to wait for news

end cash position $M 6118.40 4267.32 2254.99 1857.20 2595.80

COVID has delayed some R&D expenses and with YTD rev up 35%, the cash position has moved up for the first time in years...

personally I'm hoping to see the following;

EOY - an out licensing deal and update on COVID study results / ability to produce commerical quantities of Y-BG for clinical studies

early Q1 2021 - completed installation of PGX equipment in Edmonton, timeline for PGX commercial equipment offshore

mid 2021 - results of BG pill
<< Previous
Bullboard Posts
Next >>